Nanobiotix

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Nanobiotix and buy or sell other stocks, ETFs, and their options commission-free!

About NBTX

Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. 

CEO
Laurent Lévy
CEOLaurent Lévy
Employees
97
Employees97
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
2003
Founded2003
Employees
97
Employees97

NBTX Key Statistics

Market cap
1.74B
Market cap1.74B
Price-Earnings ratio
-62.75
Price-Earnings ratio-62.75
Dividend yield
Dividend yield
Average volume
40.98K
Average volume40.98K
High today
$36.15
High today$36.15
Low today
$31.68
Low today$31.68
Open price
$35.47
Open price$35.47
Volume
109.53K
Volume109.53K
52 Week high
$57.14
52 Week high$57.14
52 Week low
$4.18
52 Week low$4.18

NBTX News

TipRanks 4d
Nanobiotix Updates Share Capital and Voting Rights as of May 31, 2026

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Investing.com 6d
Leerink raises Nanobiotix stock price target on cancer drug data - Investing.com

...

Leerink raises Nanobiotix stock price target on cancer drug data - Investing.com

Analyst ratings

80%

of 10 ratings
Buy
80%
Hold
20%
Sell
0%

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.